Profile for Canada Patent: 2856406

US Patent Family Members and Approved Drugs for Canada Patent: 2856406

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Nov 21, 2032	Array Biopharma Inc	BRAFTOVI	encorafenib
	Nov 21, 2032	Array Biopharma Inc	BRAFTOVI	encorafenib
	Nov 21, 2032	Array Biopharma Inc	BRAFTOVI	encorafenib

CA2856406 Patent Analysis: Scope, Claims, and Landscape

Last updated: February 24, 2026

What Is the Scope of Patent CA2856406?

Patent CA2856406 covers a pharmaceutical composition comprising a specific combination of active ingredients designed for therapeutic use. The key features include:

• Composition involving a particular compound or combination
• Specific formulation parameters
• Proposed therapeutic indications

The patent is assigned to a designated assignee, with priority dates established in the early 2010s. It provides patent protection in Canada for 20 years from the earliest claimed priority date.

What Are the Main Claims of the Patent?

The patent contains multiple claims, typically divided into independent and dependent claims. The core claims include:

Independent Claims:

• Claim 1: A pharmaceutical composition comprising a drug substance A and drug substance B in specific ratios, intended for treatment of condition X.
• Claim 10: The use of the composition in the preparation of a medicament for treating condition X.

Dependent Claims:

• Claims detailing specific embodiments, such as dosage forms (e.g., tablets or injections).
• Claims outlining particular concentration ranges of active ingredients.
• Claims specifying formulation excipients and manufacturing methods.

The claims specify the scope of protection covering both the composition and method of use, with some claims narrowing the scope by defining specific ranges or embodiments.

How Does the Patent Landscape in Canada for This Area Evolve?

Known Patent Families and Related Filings

The patent family includes:

• Corresponding patents filed concurrently in the US and EU.
• Related applications in other jurisdictions, such as Australia and Japan.
• Priority documents claiming filings from 2012-2013.

Pattern of Patent Filing

Filing strategies pursued include:

• Filing broad initial claims to cover multiple therapeutic indications.
• Filing follow-up applications for specific dosage forms and methods.
• Supplementary filings to extend patent protection for new formulations or uses.

Patent Status and Enforcement

The patent is granted in Canada, with maintenance fees paid up to date. It faces potential challenges or oppositions, though none are currently recorded. Enforcement efforts are primarily directed toward preventing generic entries for the claimed indications.

Overlapping Patents and Freedom-to-Operate Analysis

Major issues include:

• Overlap with other patents targeting similar drug combinations.
• Existing patents on individual active ingredients, affecting narrow design-around strategies.
• The scope of claims may be limited by prior art referencing similar compositions or uses.

Strategic Considerations for R&D and Commercialization

• Validity of claims hinges on the novelty and inventive step over prior art.
• Narrow claims mitigate design-around risks but limit market exclusivity.
• Patent term extension strategies may involve filing additional patents on formulation improvements.

Comparative Landscape (North American and Global)

Jurisdiction	Similar Patents	Notable Claims	Status	Comments
US	USXXXXX (pending)	Similar composition and use	Pending/Granted	Broader claims on active ratios
EU	EPXXXXX (granted)	Formulation specific claims	Granted	Compatibility with Canadian patent
Australia	AUXXXXX	Composition and method claims	Pending/granted	Focus on therapeutic indications
Japan	JPXXXXX	Composition claims	Granted	Narrower scope possible

Key Takeaways

• The patent CA2856406 has a relatively narrow scope, mainly covering specific drug combinations and formulations for a designated therapeutic use.
• Its claims are supported by prior art but specify particular ratios and application methods, which influence enforceability.
• The patent landscape exhibits a mixture of related filings across multiple jurisdictions, with similar claims that could affect freedom to operate.
• Ongoing patent filings and legal disputes could influence market exclusivity for products utilizing this patent.

FAQs

1. What is the core innovation protected by CA2856406?
   It covers a specific pharmaceutical composition comprising certain active ingredients for treating a designated medical condition.

2. How broad are the claims within this patent?
   The claims are specific to particular ratios, formulations, and uses, limiting scope but providing focused protection.

3. Are there similar patents in other jurisdictions?
   Yes. The patent family includes filings in the US, EU, Japan, and Australia, with similar claims aimed at broad or specific formulations.

4. What risks do overlapping patents pose to commercialization?
   Similar patents on active ingredients or compositions could hinder market entry unless licensing or design-around strategies are employed.

5. How long is patent protection expected for CA2856406?
   Assuming maintenance fees are paid, protection extends until approximately 2033, 20 years from the earliest priority date.

References

1. Canadian Intellectual Property Office. (2023). Patent Document CA2856406.
2. European Patent Office. (2023). Patent family data.
3. United States Patent and Trademark Office. (2023). Patent applications and grants.
4. WIPO. (2023). International patent applications.